Barclays lowered the firm’s price target on Natera (NTRA) to $160 from $200 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Microsoft, Intel upgraded: Wall Street’s top analyst calls
- Natera Appoints Monica Bertagnolli to Board of Directors
- Natera initiated with an Outperform at RBC Capital
- Natera enrolls first patients in HEROES clinical trial Metastatic HER2+ BC
- Natera price target raised to $185 from $176 at Morgan Stanley